Trial Profile
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; B7-1-transduced tumour cell vaccine (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 04 Nov 2005 New trial record.